Diamyd Medical AB (publ)
Stockholm Stock ExchangeTotal Valuation
Diamyd Medical AB (publ) carries a market capitalization of 146.86M, placing it among publicly traded companies globally. Its enterprise value stands at -187.26M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 146.86M |
| Enterprise Value | -187.26M |
Share Statistics
Diamyd Medical AB (publ) currently has 154.98M shares outstanding.
| Shares Outstanding | 154.98M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 385.53, and the price-to-book ratio stands at 10.10.
| PE Ratio | N/A |
| PS Ratio | 385.53 |
| PB Ratio | 10.10 |
| P/TBV Ratio | 0.61 |
| P/FCF Ratio | -1.03 |
| P/OCF Ratio | -1.03 |
Enterprise Valuation
| EV / Sales | 9,011.28 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Diamyd Medical AB (publ) maintains a current ratio of 15.50, meaning it holds 15.5x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 15.50 |
| Quick Ratio | 15.23 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -148.16 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -59.20 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Diamyd Medical AB (publ)'s stock has declined approximately -88.8049% over the past 52 weeks. The 50-day moving average sits at 1.12, while the 200-day moving average is 8.48.
| Beta (5Y) | N/A |
| 52-Week Price Change | -88.8049% |
| 50-Day Moving Average | 1.12 |
| 200-Day Moving Average | 8.48 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Diamyd Medical AB (publ) generated 412,000.00 in revenue and converted that into -238.78M in net income, yielding earnings per share of -1.68. EBITDA reached -241.06M, while operating income came in at -241.06M.
| Revenue | 412,000.00 |
| Gross Profit | -2.28M |
| Operating Income | -241.06M |
| Pretax Income | -238.78M |
| Net Income | -238.78M |
| EBITDA | -241.06M |
| EBIT | -241.06M |
| Earnings Per Share (EPS) | -1.68 |
Balance Sheet
Total book value stands at 15.72M, with working capital of 329.46M providing operational flexibility.
| Cash & Cash Equivalents | 346.11M |
| Total Debt | N/A |
| Net Debt | -306.37M |
| Equity (Book Value) | 15.72M |
| Book Value Per Share | 0.11 |
| Working Capital | 329.46M |
Cash Flow
Diamyd Medical AB (publ) produced -154.90M in operating cash flow over the past twelve months. After subtracting -992,000.00 in capital expenditures, free cash flow totaled -155.90M - equivalent to -1.10 per share.
| Operating Cash Flow | -154.90M |
| Capital Expenditures | -992,000.00 |
| Free Cash Flow | -155.90M |
| FCF Per Share | -1.10 |
Margins
Diamyd Medical AB (publ) operates with a gross margin of -552.43, reflecting its pricing power and cost economics. The operating margin of -58,509.95 and net profit margin of -57,956.80 provide insight into operational efficiency.
| Gross Margin | -552.43 |
| Operating Margin | -58,509.95 |
| Pretax Margin | -57,956.80 |
| Profit Margin | -57,956.80 |
| EBITDA Margin | -58,509.95 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -141.53 |
| FCF Yield | -96.90 |
Stock Splits
Diamyd Medical AB (publ)'s most recent stock split took place on May 30, 2023 with a 125:128 split ratio.
| Last Split Date | 5/30/2023 |
| Split Ratio | 125:128 |
Scores
Diamyd Medical AB (publ) posts an Altman Z-Score of -0.34, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -0.34 |